IPG Photonics (IPGP) Proxy filing summary

Executive summary

• Achieved $1.004B in revenue for 2025, with 3% year-over-year growth and a 38% gross margin, marking the first annual revenue increase since 2021.

• Expanded into new industrial and non-industrial markets, including medical, micromachining, and defense, with notable product launches and FDA clearance for a new urology system.

• Ended 2025 with $839M in cash and no debt, enabling strategic investments and $50M in share repurchases; authorized a new $100M buyback program.

• Board and management focused on operational discipline, strategic clarity, and a team-led operating model to drive long-term shareholder value.

Voting matters and shareholder proposals

• Election of ten directors, all current members, to serve until the 2027 annual meeting.

• Advisory vote to approve executive compensation, with the Board recommending approval.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026.

Board of directors and corporate governance

• Board consists of ten directors, seven of whom are independent; average tenure is eight years.

• Board committees (Audit, Compensation, Nominating and Corporate Governance) are composed entirely of independent directors.

• Non-executive Chair leads the Board; independent directors meet in executive session quarterly.

• Annual self-assessments and bi-annual committee evaluations ensure effective governance.

• Board refreshment ongoing, with over half of nominees joining since 2021.